F-GYN injection for vaginal dryness and vaginal/vestibular atrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, open-label study conducted at multiple centers to evaluate the safety and effectiveness of a non-crosslinked hyaluronic acid injectable gel (F-GYN) in adult women with moderate to severe vaginal dryness and signs of vaginal or vestibular atrophy. Participants are randomized 2:1 to receive an immediate F-GYN injection or 4 weeks of standard non-hormonal care, after which the control group also receives the injection and all participants are followed with gynecological assessments and patient-reported outcomes. The study includes safety monitoring for adverse events and uses clinician assessments along with questionnaires to gauge tolerability and symptom changes. Primary comparisons focus on symptom relief and mucosal moisture, with follow-up to assess durability of response after treatment. Eligible participants are adult women with documented vaginal mucosal moisture loss, vaginal dryness, and a baseline pain/dispcomfort during intercourse, who are not using hormonal therapies for vaginal symptoms during the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female participants.
* Age over 18 years.
* Decreased moisture of the vaginal and/or vestibular mucosa confirmed by the investigator during gynecological examination, defined as a moisture/fluid volume domain score of 3 or less on a 5-point scale.
* Participant-reported vaginal dryness and/or pain during sexual intercourse with a score of at least 5 on an 11-point numeric rating scale at the baseline visit.
* Willingness not to use intravaginal or systemic hormonal therapies for the treatment of vaginal dryness or vaginal atrophy during the study. Stable hormonal contraception without planned changes during the study is allowed.
* Willingness to report all medications, intravaginal products, vaginal gels, creams, suppositories, lubricants, and other products used to relieve symptoms of vaginal dryness during the study.
* Ability and willingness to provide voluntary written informed consent before any study-related procedures.
* For participants of childbearing potential: negative urine pregnancy test at the baseline visit and, for participants assigned to the control arm, also before F-GYN injection; willingness to use a method of contraception accepted by the investigator throughout the study.

Exclusion Criteria:

* Menstruation or genital tract bleeding of unknown cause on the day of the screening/baseline visit.
* Pregnancy, breastfeeding, or planned pregnancy during the study.
* Presence of varices, open wounds, ulcers, active infections, or other clinically significant damage of the vaginal or vestibular mucosa at the planned injection sites.
* Tendency to develop hypertrophic scars or keloids.
* Active vaginal or vulvar infection, including viral, bacterial, or fungal infection.
* Active urinary tract infection.
* Other genital tract conditions that, in the investigator's opinion, could affect assessment of study outcomes.
* Severe disease or other medical condition that, in the investigator's opinion, could affect assessment of study outcomes or participant safety.
* Local treatment in the study area within 4 weeks before the baseline visit that could significantly affect study outcomes, including intravaginal hormonal products such as suppositories, creams, or vaginal tablets.
* Use of intravaginal products containing hyaluronic acid or other substances with a potentially long-lasting effect on vaginal mucosal atrophy within 4 weeks before the baseline visit.
* Systemic hormonal therapy or estrogen receptor modulation, such as selective estrogen receptor modulators, that could affect the vaginal mucosa within 8 weeks before the baseline visit.
* Anti-estrogen therapy, including tamoxifen or aromatase inhibitors, for hormone-dependent breast cancer within 12 months before the baseline visit.
* Injection procedures at the planned injection sites, such as hyaluronic acid, platelet-rich plasma, or other injectable therapies, within 6 months before the start of the study.
* Device-based procedures with potential effects on vaginal mucosal atrophy at the planned treatment area, such as CO₂ laser, radiofrequency, or similar procedures, within 6 months before the start of the study.
* Use of anticoagulant or antiplatelet medication.
* Clinically significant coagulation disorder.
* Known hypersensitivity to any component of the investigational device, local anesthetic, or antiseptic solution.
* Current participation or planned participation in another clinical study during participation in the F-GYN study.

Where it's running

• Salus
  Bolesławice, Poland Recruiting
• Centermed
  Elblag, Poland Recruiting
• Victoria Clinic
  Gdansk, Poland Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nonhormonal vulvovaginal gel to relieve menopausal vulvovaginal symptoms

  This will test a hormone-free vulvovaginal gel in postmenopausal women with genitourinary syndrome of menopause to see if it reduces vaginal atrophy symptoms and improves daily quality of life.

  Recruiting Mucosa Innovations, S.L. · Madrid, Madrid · NCT06962345

• Treatment for vaginal atrophy and related conditions using a novel gel dressing

  This study is testing a new gel dressing to see if it can help adult women with vaginal atrophy and other skin conditions feel better.

  Recruiting at 6 sites Stratpharma AG · Birmingham, Alabama and 13 other locations · NCT05953090

• Sexual Health in Spanish-Speaking Adults: A Large Online Survey

  A large online survey will test sexual health, sexual behavior, and sexual function in Spanish-speaking adults to see how common these experiences are and to explore unusual states of consciousness during orgasm.

  Recruiting Menoclinica by Palacios · Santander, Cantabria and 1 other locations · NCT07746297

• Vaginal DHEA vs Vaginal Estrogen for Menopause Symptoms

  This study tests whether vaginal DHEA or vaginal estrogen helps with vaginal dryness, discomfort, and urinary symptoms in peri- or post-menopausal women by randomly assigning participants to one treatment and measuring their symptoms over time.

  Recruiting University of Arizona · Phoenix, Arizona · NCT07574216

• Radiofrequency combined with ultrasound for postpartum sexual pain

  This study will try a combined radiofrequency and ultrasound treatment (BTL Exilis) to reduce pain during sex in women who developed dyspareunia after a vaginal delivery.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Tarragona, TARRAGONA · NCT07504991

• Wheat polar lipid supplement for vaginal dryness in postmenopausal women

  This trial will test whether a daily wheat polar lipid dietary supplement can reduce vaginal dryness in healthy postmenopausal women.

  Recruiting Seppic · Louvain-la-Neuve, Belgium · NCT07386249

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.